# Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure

Study · id `cardio:ct-nct07656168` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07656168](<https://clinicaltrials.gov/study/NCT07656168>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07656168

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07656168. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2028-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07656168, source copy `cardio:ctgov-nct07656168-2026-06-25`, retrieved 2026-10-26)
- Started: 2026-06-01 (actual) (ClinicalTrials.gov record NCT07656168, source copy `cardio:ctgov-nct07656168-2026-06-25`, retrieved 2026-10-26)
- Primary completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07656168, source copy `cardio:ctgov-nct07656168-2026-06-25`, retrieved 2026-10-26)
- Completion: 2028-08 (anticipated) (ClinicalTrials.gov record NCT07656168, source copy `cardio:ctgov-nct07656168-2026-06-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07656168, source copy `cardio:ctgov-nct07656168-2026-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07656168-2026-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure
- Acronym: PHOENIX
- Condition: ESRD (End-Stage Renal Disease)
- Condition: Maintenance Hemodialysis
- Intervention (Device): pHA130 Hemoadsorption Cartridge
- Intervention (Device): High-flux Hemodialyzer
- Lead sponsor: China-Japan Friendship Hospital
- Lead sponsor class: OTHER
- Collaborator: Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: China-Japan Friendship Hospital (`cardio:org-china-japan-friendship-hospital`)

## Provenance

Content hash: b314d31260c7127d2c2e84a6d7a481cbff15c07285d0919c0e06513f8781764c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
